6972-78-7

Basic information

• Product Name: 6-AMINO-1-METHYL-5-NITROSOURACIL
• Synonyms: TIMTEC-BB SBB003857;6-AMINO-1-METHYL-5-NITROSOURACIL;LABOTEST-BB LT00154623;6-amino-1-methyl-5-nitroso-1h-pyrimidine-2,4-dione;6-AMINO-1-METHYL-5-NITROSOURAC;6-Amino-1-methyl-5-nitroso-2,4(1H,3H)-pyrimidinedione;6-Amino-1-methyl-5-nitrosouracil,97%;3-Methyl-4-amino-5-nitrosouracil
• CAS NO: 6972-78-7
• Molecular Formula: C₅H₆N₄O₃
• Molecular Weight: 170.13
• EINECS: 230-213-6
• Mol File: 6972-78-7.mol
• Article Data: 22

Chemical Properties

• Melting Point: >300 °C(lit.)
• Appearance: crystalline powder
• Density: 1.83
• Refractive Index: 1.742
• Storage Temp.: Amber Vial, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO
• PKA: 7.08±0.40(Predicted)
• Stability: Light and temperature sensitive
• CAS DataBase Reference: 6-AMINO-1-METHYL-5-NITROSOURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-1-METHYL-5-NITROSOURACIL(6972-78-7)
• EPA Substance Registry System: 6-AMINO-1-METHYL-5-NITROSOURACIL(6972-78-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 6972-78-7(Hazardous Substances Data)

Usage

Uses

6-Amino-1-methyl-5-nitrosouracil is known to exhibit anitmicrobial activity and form complexation with platinum (II).

InChI:InChI=1/C5H6N4O3/c1-9-3(6)2(8-12)4(10)7-5(9)11/h6H2,1H3,(H,7,10,11)

Upstream product

• 59653-14-4 N-(cyano-hydroxyimino-acetyl)-N'-methyl-urea 
• 17743-03-2 1-Methyl-6-imino-uracil 
• 2434-53-9 6-amino-1-methyluracil 
• 6972-77-6 N-cyanoacetyl-N'-methyl-urea 
• 623-59-6 N-acetyl-N'-methylurea 

Downstream Products

• 14785-95-6 3-methyl-4-amino-5-formylamino-2,6-dioxypyrimidine 
• 6972-82-3 5,6-diamino-1-methyluracil 
• 1076-22-8 3-methylxanthine 
• 64233-24-5 1-methyl-6-phenylpteridine-2,4-dione 
• 2850-34-2 3-methyl-8-phenylxanthine 
• 6703-92-0 8-Mercaptotheobromin 
• 83-67-0 theobromine / 
• 15371-15-0 8-bromo-3,7-dimethylxanthine 
• 93703-24-3 3-methyl-8-bromoxanthine 
• 666816-98-4 8-bromo-7-(but2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6–dione 
• 853029-57-9 2-bromo-1-(but-2-ynyl)-4-methyl-6-((4-methylquinazolin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-5,7-(4H,6H)-dione 
• 668270-12-0 Linagliptin 
• 1192216-03-7 8-(2-methoxyphenyl)-1-methyl-7-(2-methyl-5-hydroxyphenyl)-1H-imidazo[2,1-f]-purine-2,4(3H,8H)-dione 
• 1192215-84-1 8-bromo-3,7-dihydro-3-methyl-7-[2-(2-methyl-5-hydroxyphenyl)-2-oxoethyl]-1H-purine-2,6-dione 

Relevant articles and documents

Linagliptin intermediate compound IV

The invention belongs to the field of pharmaceutical chemicals, and discloses a linagliptin intermediate IV and a novel route for synthesizing an important linagliptin intermediate from the linagliptin intermediate IV. The linagliptin intermediate IV synthesized in the invention has the advantages of high yield, simple operation, substantial reduction of production cost, suitableness for industrial production; and the synthesis route solves the problems of self-coupling of linagliptin intermediates and generation of large impurities in the prior art.

Synthesis, radiolabelling and initial biological characterisation of 18F-labelled xanthine derivatives for PET imaging of Eph receptors

Eph receptor tyrosine kinases, particularly EphA2 and EphB4, represent promising candidates for molecular imaging due to their essential role in cancer progression and therapy resistance. Xanthine derivatives were identified to be potent Eph receptor inhibitors with IC50 values in the low nanomolar range (1-40 nm). These compounds occupy the hydrophobic pocket of the ATP-binding site in the kinase domain. Based on lead compound 1, we designed two fluorine-18-labelled receptor tyrosine kinase inhibitors ([18F]2/3) as potential tracers for positron emission tomography (PET). Docking into the ATP-binding site allowed us to find the best position for radiolabelling. The replacement of the methyl group at the uracil residue ([18F]3) rather than the methyl group of the phenoxy moiety ([18F]2) by a fluoropropyl group was predicted to preserve the affinity of the lead compound 1. Herein, we point out a synthesis route to [18F]2 and [18F]3 and the respective tosylate precursors as well as a labelling procedure to insert fluorine-18. After radiolabelling, both radiotracers were obtained in approximately 5% radiochemical yield with high radiochemical purity (>98%) and a molar activity of >10 GBq μmol-1. In line with the docking studies, first cell experiments revealed specific, time-dependent binding and uptake of [18F]3 to EphA2 and EphB4-overexpressing A375 human melanoma cells, whereas [18F]2 did not accumulate at these cells. Since both tracers [18F]3 and [18F]2 are stable in rat blood, the novel radiotracers might be suitable for in vivo molecular imaging of Eph receptors with PET.

Substituted xanthine compound and its preparation and use (by machine translation)

The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.